ESMO 2019 | IMvigor130: atezolizumab +/- platinum-based chemo upfront for advanced urothelial carcinoma

Enrique Grande, MD, from the MD Anderson Cancer Center Madrid, Madrid, Spain, presents the results of IMvigor130 – testing atezolizumab as a single agent or combined with platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. Angela Lamarca, MD, PhD, from The Christie NHS Foundation Trust, Manchester, UK, then discusses these results.